$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000140191424000038 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$41.69K	$22.44K
YoY Change	-95.83%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$41.69K	$22.44K
YoY Change
Gross Profit Margin	100.0%	100.01%
Selling, General & Admin	$2.066M	$2.473M
YoY Change	-24.03%	-16.04%
% of Gross Profit	4956.27%	11021.08%
Research & Development	$2.657M	$4.909M
YoY Change	-60.2%	-18.78%
% of Gross Profit	6372.68%	21875.11%
Depreciation & Amortization	$9.740K	$15.44K
YoY Change	-2.6%	60.67%
% of Gross Profit	23.36%	68.81%
Operating Expenses	$4.723M	$7.382M
YoY Change	-49.74%	-17.88%
Operating Profit	-$4.681M	-$7.359M
YoY Change	-44.25%	-18.13%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$21.15K	-$109.3K
YoY Change	-121.73%	-148.1%
Pretax Income	-$4.703M	$12.91M
YoY Change	-43.34%	-247.34%
Income Tax
% Of Pretax Income
Net Earnings	-$4.703M	$12.91M
YoY Change	-43.34%	-247.34%
Net Earnings / Revenue	-11279.42%	57539.25%
Basic Earnings Per Share	-$0.55	$1.53
Diluted Earnings Per Share	-$0.55	$1.52
COMMON SHARES
Basic Shares Outstanding	8.546M shares	101.1M shares
Diluted Shares Outstanding	8.534M shares	8.476M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.23M	$16.41M
YoY Change	-19.13%	23.15%
Cash & Equivalents	$11.20M	$16.40M
Short-Term Investments
Other Short-Term Assets	$3.195M	$3.512M
YoY Change	284.27%	1190.81%
Inventory
Prepaid Expenses	$3.195M	$3.512M
Receivables
Other Receivables	$518.9K	$902.2K
Total Short-Term Assets	$14.95M	$20.83M
YoY Change	-33.38%	-6.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$706.3K	$322.3K
YoY Change	1104.74%	603.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$533.9K	$528.6K
YoY Change	-32.96%	-42.6%
Total Long-Term Assets	$3.113M	$2.777M
YoY Change	18.87%	187.25%
TOTAL ASSETS
Total Short-Term Assets	$14.95M	$20.83M
Total Long-Term Assets	$3.113M	$2.777M
Total Assets	$18.06M	$23.61M
YoY Change	-27.92%	1.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.049M	$1.910M
YoY Change	-78.97%	-70.8%
Accrued Expenses	$1.851M	$1.254M
YoY Change	-65.03%	-70.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.16M	$14.59M
YoY Change	-50.06%	-40.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.388M	$6.345M
YoY Change	538.76%	416.45%
Total Long-Term Liabilities	$6.388M	$6.345M
YoY Change	538.76%	416.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.16M	$14.59M
Total Long-Term Liabilities	$6.388M	$6.345M
Total Liabilities	$19.54M	$20.93M
YoY Change	-28.52%	-19.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$169.8M	-$165.1M
YoY Change	2.17%	4.56%
Common Stock	$168.7M	$168.1M
YoY Change	2.65%	8.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.484M	$2.672M
YoY Change
Total Liabilities & Shareholders Equity	$18.06M	$23.61M
YoY Change	-27.92%	1.71%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$4.703M	$12.91M
YoY Change	-43.34%	-247.34%
Depreciation, Depletion And Amortization	$9.740K	$15.44K
YoY Change	-2.6%	60.67%
Cash From Operating Activities	-$5.924M	$12.90M
YoY Change	-25.76%	-295.93%
INVESTING ACTIVITIES
Capital Expenditures	-$282.3K	$285.2K
YoY Change	-1511.6%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$282.3K	-$285.2K
YoY Change	-1511.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	436.4K	115.4K
YoY Change	-94.91%	-74.49%
NET CHANGE
Cash From Operating Activities	-5.924M	12.90M
Cash From Investing Activities	282.3K	-285.2K
Cash From Financing Activities	436.4K	115.4K
Net Change In Cash	-5.205M	12.73M
YoY Change	-997.47%	-307.61%
FREE CASH FLOW
Cash From Operating Activities	-$5.924M	$12.90M
Capital Expenditures	-$282.3K	$285.2K
Free Cash Flow	-$5.642M	$12.62M
YoY Change	-29.48%	-291.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#LicenseMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#RoyaltyMember
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22438	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22005	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4971600	usd
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#LicenseMember
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8546361	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8546361	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	36.00
CY2018Q1	dare	Estimated Fair Value Of Warrants Recorded In Equity EstimatedFairValueOfWarrantsRecordedInEquity	3000000.0	usd
CY2019Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	11.76
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	11.52
CY2024Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	3500000	usd
	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y1M13D
	us-gaap	Operating Lease Cost OperatingLeaseCost	391000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	145000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	284000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	318000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	105000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	209000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#LicenseMember
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31740	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	215113	usd
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	20379376	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-109254	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	227124	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-842137	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	567272	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8762232	usd
	us-gaap	Net Income Loss NetIncomeLoss	6155300	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14563	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31151	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-24664	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-53156	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12925219	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8793383	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16857889	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.32
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.32
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8411242	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7200260	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7248011	shares
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	215113	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6755356	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-10999410	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	182978	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11112110	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	624621	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1299375	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	650186	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	452195	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8762232	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31151	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2719402	usd
	us-gaap	Net Income Loss NetIncomeLoss	6155300	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16804733	usd
	us-gaap	Depreciation Depreciation	26215	usd
	us-gaap	Depreciation Depreciation	19123	usd
	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-181775	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1190418	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1274807	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-600000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	dare	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	22438	usd
	dare	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	0	usd
	dare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	170864	usd
	dare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27979	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-75016	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1130694	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2605983	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1403634	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-683370	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	3939	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	272100	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-36023	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	40995	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-237949	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-193586	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-1475791	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	4513162	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1367460	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6700216	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	247520	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	2799491	usd
	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	4609482	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	205206	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6091723	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22703918	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	292522	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-292522	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	398091	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	452195	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	12910656	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2671506	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11112110	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	624621	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1299375	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	650186	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	452195	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31151	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2719402	usd
	us-gaap	Net Income Loss NetIncomeLoss	6155300	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16804733	usd
	us-gaap	Depreciation Depreciation	26215	usd
	us-gaap	Depreciation Depreciation	19123	usd
	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-232122	usd
	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-181775	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1190418	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1274807	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-600000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	dare	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	22438	usd
	dare	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	0	usd
	dare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	170864	usd
	dare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-75016	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1130694	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2605983	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1403634	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-683370	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	3939	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	272100	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	40995	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-237949	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-1475791	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	4513162	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1367460	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6700216	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	247520	usd
	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	2799491	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	205206	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6091723	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22703918	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	292522	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-292522	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	398091	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	452195	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1299375	usd
	dare	Repayment Of Liability On Sale Future Royalties RepaymentOfLiabilityOnSaleFutureRoyalties	1505	usd
	dare	Repayment Of Liability On Sale Future Royalties RepaymentOfLiabilityOnSaleFutureRoyalties	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	267188	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1299375	usd
	dare	Repayment Of Liability On Sale Future Royalties RepaymentOfLiabilityOnSaleFutureRoyalties	1505	usd
	dare	Repayment Of Liability On Sale Future Royalties RepaymentOfLiabilityOnSaleFutureRoyalties	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	267188	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129398	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1751570	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-24663	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-53156	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5903936	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21005504	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10811056	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34669605	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16714992	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13664101	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16414992	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13329101	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	300000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16714992	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13664101	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129398	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1751570	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-24663	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-53156	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21005504	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10811056	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34669605	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13664101	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16414992	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13329101	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	300000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	335000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16714992	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13664101	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	358315	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	300000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	300000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165100000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16400000	usd
CY2024Q2	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	10900000	usd
CY2024Q2	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	6200000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	6200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	6100000	usd
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	20400000	usd
	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2024Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	400000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1400000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	191000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165100000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16400000	usd
CY2024Q2	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	10900000	usd
CY2024Q2	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	6200000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	6200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	6100000	usd
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	20400000	usd
	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	191000	usd
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	159000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M1D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1050
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	297000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	660000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	680000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	130000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1767000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	242000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1525000	usd
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	159000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M1D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1050
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	680000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	130000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1767000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	242000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1525000	usd
CY2023Q3	dare	Insurance Financing Premiums Taxes And Fees Amount InsuranceFinancingPremiumsTaxesAndFeesAmount	600000	usd
CY2023Q3	dare	Insurance Financing Interest Rate InsuranceFinancingInterestRate	0.080
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2165014	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	789727	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2163051	shares
CY2023Q3	dare	Insurance Financing Premiums Taxes And Fees Amount InsuranceFinancingPremiumsTaxesAndFeesAmount	600000	usd
CY2023Q3	dare	Insurance Financing Interest Rate InsuranceFinancingInterestRate	0.080
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2165014	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	789727	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2163051	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	789727	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	789727	shares
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001401914-24-000038-index-headers.html	Edgar Link	pending
0001401914-24-000038-index.html	Edgar Link	pending
0001401914-24-000038.txt	Edgar Link	pending
0001401914-24-000038-xbrl.zip	Edgar Link	pending
dare-20240630.htm	Edgar Link	pending
dare-20240630.xsd	Edgar Link	pending
dare-20240630_g1.jpg	Edgar Link	pending
exhibit101xoma-daretradi.htm	Edgar Link	pending
exhibit101xoma-daretradi001.jpg	Edgar Link	pending
exhibit101xoma-daretradi002.jpg	Edgar Link	pending
exhibit101xoma-daretradi003.jpg	Edgar Link	pending
exhibit101xoma-daretradi004.jpg	Edgar Link	pending
exhibit101xoma-daretradi005.jpg	Edgar Link	pending
exhibit101xoma-daretradi006.jpg	Edgar Link	pending
exhibit101xoma-daretradi007.jpg	Edgar Link	pending
exhibit101xoma-daretradi008.jpg	Edgar Link	pending
exhibit101xoma-daretradi009.jpg	Edgar Link	pending
exhibit101xoma-daretradi010.jpg	Edgar Link	pending
exhibit101xoma-daretradi011.jpg	Edgar Link	pending
exhibit101xoma-daretradi012.jpg	Edgar Link	pending
exhibit101xoma-daretradi013.jpg	Edgar Link	pending
exhibit101xoma-daretradi014.jpg	Edgar Link	pending
exhibit101xoma-daretradi015.jpg	Edgar Link	pending
exhibit101xoma-daretradi016.jpg	Edgar Link	pending
exhibit101xoma-daretradi017.jpg	Edgar Link	pending
exhibit101xoma-daretradi018.jpg	Edgar Link	pending
exhibit101xoma-daretradi019.jpg	Edgar Link	pending
exhibit101xoma-daretradi020.jpg	Edgar Link	pending
exhibit101xoma-daretradi021.jpg	Edgar Link	pending
exhibit101xoma-daretradi022.jpg	Edgar Link	pending
exhibit101xoma-daretradi023.jpg	Edgar Link	pending
exhibit101xoma-daretradi024.jpg	Edgar Link	pending
exhibit101xoma-daretradi025.jpg	Edgar Link	pending
exhibit101xoma-daretradi026.jpg	Edgar Link	pending
exhibit101xoma-daretradi027.jpg	Edgar Link	pending
exhibit101xoma-daretradi028.jpg	Edgar Link	pending
exhibit101xoma-daretradi029.jpg	Edgar Link	pending
exhibit101xoma-daretradi030.jpg	Edgar Link	pending
exhibit101xoma-daretradi031.jpg	Edgar Link	pending
exhibit101xoma-daretradi032.jpg	Edgar Link	pending
exhibit101xoma-daretradi033.jpg	Edgar Link	pending
exhibit101xoma-daretradi034.jpg	Edgar Link	pending
dare-20240630_cal.xml	Edgar Link	unprocessable
dare-20240630_lab.xml	Edgar Link	unprocessable
dare-20240630_pre.xml	Edgar Link	unprocessable
exhibit101xoma-daretradi035.jpg	Edgar Link	pending
exhibit101xoma-daretradi036.jpg	Edgar Link	pending
exhibit101xoma-daretradi037.jpg	Edgar Link	pending
exhibit101xoma-daretradi038.jpg	Edgar Link	pending
exhibit101xoma-daretradi039.jpg	Edgar Link	pending
exhibit103amendmentno3gate.htm	Edgar Link	pending
exhibit104_amendedrestated.htm	Edgar Link	pending
exhibit105amendmentno2toem.htm	Edgar Link	pending
exhibit106darebiosciencein.htm	Edgar Link	pending
exhibit107dare-2022stockin.htm	Edgar Link	pending
exhibit311_20240630.htm	Edgar Link	pending
exhibit31_amendedandrestat.htm	Edgar Link	pending
exhibit321_20240630.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xoma-daresyntheticroyalt.htm	Edgar Link	pending
xoma-daresyntheticroyalt001.jpg	Edgar Link	pending
xoma-daresyntheticroyalt002.jpg	Edgar Link	pending
xoma-daresyntheticroyalt003.jpg	Edgar Link	pending
xoma-daresyntheticroyalt004.jpg	Edgar Link	pending
xoma-daresyntheticroyalt005.jpg	Edgar Link	pending
xoma-daresyntheticroyalt006.jpg	Edgar Link	pending
xoma-daresyntheticroyalt007.jpg	Edgar Link	pending
xoma-daresyntheticroyalt008.jpg	Edgar Link	pending
xoma-daresyntheticroyalt009.jpg	Edgar Link	pending
xoma-daresyntheticroyalt010.jpg	Edgar Link	pending
xoma-daresyntheticroyalt011.jpg	Edgar Link	pending
xoma-daresyntheticroyalt012.jpg	Edgar Link	pending
xoma-daresyntheticroyalt013.jpg	Edgar Link	pending
xoma-daresyntheticroyalt014.jpg	Edgar Link	pending
xoma-daresyntheticroyalt015.jpg	Edgar Link	pending
xoma-daresyntheticroyalt016.jpg	Edgar Link	pending
xoma-daresyntheticroyalt017.jpg	Edgar Link	pending
xoma-daresyntheticroyalt018.jpg	Edgar Link	pending
xoma-daresyntheticroyalt019.jpg	Edgar Link	pending
xoma-daresyntheticroyalt020.jpg	Edgar Link	pending
xoma-daresyntheticroyalt021.jpg	Edgar Link	pending
xoma-daresyntheticroyalt022.jpg	Edgar Link	pending
xoma-daresyntheticroyalt023.jpg	Edgar Link	pending
xoma-daresyntheticroyalt024.jpg	Edgar Link	pending
xoma-daresyntheticroyalt025.jpg	Edgar Link	pending
xoma-daresyntheticroyalt026.jpg	Edgar Link	pending
xoma-daresyntheticroyalt027.jpg	Edgar Link	pending
xoma-daresyntheticroyalt028.jpg	Edgar Link	pending
xoma-daresyntheticroyalt029.jpg	Edgar Link	pending
xoma-daresyntheticroyalt030.jpg	Edgar Link	pending
xoma-daresyntheticroyalt031.jpg	Edgar Link	pending
xoma-daresyntheticroyalt032.jpg	Edgar Link	pending
xoma-daresyntheticroyalt033.jpg	Edgar Link	pending
xoma-daresyntheticroyalt034.jpg	Edgar Link	pending
xoma-daresyntheticroyalt035.jpg	Edgar Link	pending
xoma-daresyntheticroyalt036.jpg	Edgar Link	pending
xoma-daresyntheticroyalt037.jpg	Edgar Link	pending
xoma-daresyntheticroyalt038.jpg	Edgar Link	pending
xoma-daresyntheticroyalt039.jpg	Edgar Link	pending
dare-20240630_htm.xml	Edgar Link	completed
dare-20240630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2024 Q3 Form 10-Q Financial Statement

#000140191424000038 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2024 Q3 Form 10-Q Financial Statement

#000140191424000038 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare